Plain-English translation of NCT07353723 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II study testing a new approach to treating locally advanced tonsillar cancer (a type of head and neck cancer). The trial combines three medications — , , and chemotherapy drugs — that are given before surgery. The goal is to see whether this combination treatment can shrink the cancer more effectively and improve survival compared to what doctors know from past experience.
Tonsillar cancer that has grown beyond the tonsil (locally advanced) is serious and difficult to treat. This trial explores whether combining immunotherapy medications with traditional chemotherapy might work better than standard approaches, potentially helping patients have better outcomes and longer survival.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the three medications over several cycles (2–4 rounds), with each round spaced 3 weeks apart. Each infusion takes at least 60 minutes, and you'll be monitored closely for side effects. Around day 42, you'll have an endoscopy (a small camera to look inside your throat) and imaging scans to see how the cancer has responded. After that, you would have surgery to remove any remaining cancer. You'll then be followed for up to 5 years after enrollment to track how well the treatment worked and your overall health.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Tang-Du Hospital
Enrollment target
~10 participants
Started
November 2025
Primary completion
November 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhao DaQing
Tangdu Hospital, Air Force Medical University (AFMU), Xi'an, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.